Jun 16, 2015, 12:06 ET
NEW YORK, June 16, 2015 /PRNewswire-USNewswire/ -- New data shows that MRI-guided targeted ablation (destruction) of prostate cancer by the use of a laser fiber is 96% effective with no urinary or sexual side effects. This is a "game changer" for prostate cancer patients, according to the Sperling Prostate Center.
Dr. Dan Sperling, Medical Director of the Sperling Prostate Center and the leading pioneer of focal laser ablation (FLA) of the prostate, states, "FLA is a response to what men want. With over 500 patients treated at our Center, we can confidently say that FLA offers the greatest promise of cancer control with less than 2% risk of any side effects. There is no surgery or radiation and no other treatment can match laser's ability to preserve urinary and sexual function. If needed, all future options including repeat FLA or whole gland therapies are still open."
The respected journal European Urology (May 2015) carries the latest research report from NYU School of Medicine and the Sperling Prostate Center (http://www.ncbi.nlm.nih.gov/pubmed/25979568). Of the 25 consecutive patients with low-to-moderate risk cancer, none experienced urinary incontinence at any time. Within 3 months, all men reported return to pre-treatment sexual function. Follow-up needle biopsies showed no cancer in 96% of the treated tumors.
Focal laser ablation is a minimally invasive outpatient procedure that requires no general anesthesia, no surgery and no radiation. FLA precisely targets any tumor seen on state-of-the-art 3T multiparametric MRI. Recovery is very rapid with most patients back to normal activity in 1-3 days.
Although not all prostate cancer patients are qualified for FLA, 3T multiparametric MRI identifies suspicious areas with excellent accuracy. Following image detection, a selective targeted biopsy into the area provides a diagnosis. The combination of MRI and biopsy determines if a man is a candidate for FLA. Long term results have not yet been established in clinical trials. Laser ablation for tumors in soft tissue is FDA cleared.
About Sperling Prostate Center
Sperling Prostate Center (New York, Florida) is the leading U.S. center for 3T multiparametric detection, diagnosis and image-guided focal treatment of prostate cancer. www.sperlingprostatecenter.com
Sperling Prostate Center (New York, Florida)
FAX (973) 740-2003
Logo - http://photos.prnewswire.com/prnh/20150616/223431LOGO
SOURCE Sperling Prostate Center
Share this article